A comparative study of the in vitro activities of XRP 2868, a new oral streptogramin, against 266 anaerobic gram-positive clinical isolates using the agar dilution method showed that the XRP 2868 MICs for 95% (254 of 266) of isolates were <0.5 g/ml. XRP 2868 MICs for only two strains, one being Clostridium clostridioforme (MIC, 16 g/ml) and the other being Clostridium difficile (MIC, 32 g/ml), were >2 g/ml. Depending on its pharmacokinetics and pharmacodynamics, XRP 2868 has potential for use against infections with grampositive anaerobes and deserves further clinical evaluation.
Streptogramins are naturally occurring bacteriostatic antibiotics derived from Streptomyces pristinaspiralis and act on the 50S ribosome by inhibition of protein synthesis (6) . Derivatives include pristinamycin, which has been available in Europe for Ͼ30 years, and quinupristin-dalfopristin, which is available as an injectable combination agent in the United States. While individual streptogramins are bacteriostatic, group A and B streptogramins given in combination act synergistically and may be bactericidal.
XRP 2868 is a new oral streptogramin that is comprised of a mixture of 70% RPR 132552A (group A, PII component) and 30% RPR 202868 (group B, PI component). Pankuch et al. (5) studied the activities of XRP 2868 against 261 pneumococci and 150 Haemophilus influenzae strains and found that XRP 2868 "showed potent activity" against all strains "irrespective of their susceptibility to other agents."
Barriere et al. The results of our study are shown in Table 1 . Overall, XRP 2868 had excellent activity against a broad range of gram-positive anaerobic bacteria, including actinomycetes, clostridia, eubacteria, Propionibacterium species, and peptostreptococci. Overall, XRP 2868 MICs for 95% (254 of 266) of isolates were Յ0.5 g/ml. XRP 2868 MICs for only two strains, one being Clostridium difficile and the other being Clostridium clostridioforme, were Ͼ2 g/ml. XRP 2868 was generally similar to or 1 dilution more active in vitro than pristinamycin and often 1 to 4 dilutions more active than quinupristin-dalfopristin. For the C. clostridioforme isolate for which the XRP MIC was 16 g/ml, pristinamycin MICs were 16 g/ml, quinupristin-dalfopristin MICs were 8 on August 28, 2017 by guest http://aac.asm.org/ g/ml, daptomycin MICs were 8 g/ml, and ampicillin, clarithromycin, and telithromycin MICs were Ͼ32 g/ml. The vancomycin MICs were 1 g/ml, and the linezolid and clindamycin MICs were 2 g/ml. In comparison, for the C.
difficile isolate for which the XRP MIC was 32 g/ml, pristinamycin MICs were 16 g/ml; clarithromycin, telithromycin, and clindamycin MICs were Ͼ32 g/ml; linezolid MICs were 8 g/ml; ampicillin and quinupristin-dalfopristin MICs a 50% and 90%, MICs at which 50 and 90% of isolates tested, respectively, were inhibited. b Actinomyces meyeri (n ϭ 5) and Actinomyces turicensis (n ϭ 7). c Eubacterium contortum (n ϭ 2), Eubacterium moniliforme (n ϭ 1), Eubacterium tenue (n ϭ 2), Pseudoramibacter alactolyticus (n ϭ 7), and Eubacterium sp., no good fit (n ϭ 1).
d Includes Lactobacillus acidophilus (n ϭ 2), Lactobacillus catenaforme (n ϭ 8), Lactobacillus gasseri (n ϭ 1), Lactobacillus jensenii (n ϭ 2), Lactobacillus leichmannii (n ϭ 1), Lactobacillus rhamnosus (n ϭ 1) and Lactobacillus uli (n ϭ 1).
e Formerly Peptostreptococcus sp. 
